Search

Your search keyword '"Weisel K"' showing total 20 results
Start Over Author "Weisel K" Publisher elsevier bv
20 results on '"Weisel K"'

1. P18 Adjusted Comparison of Teclistamab Versus Real-World Physician’s Choice (RWPC) of Therapy in Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Author

Mateos, M.V., primary, Chari, A., additional, Usmani, S.Z., additional, Goldschmidt, H., additional, Weisel, K., additional, Qi, K., additional, Londhe, A., additional, Nair, S., additional, Lin, X., additional, Pei, L., additional, Ammann, E., additional, Chastain, K., additional, Parekh, T., additional, Marshall, A., additional, Slavcev, M., additional, and Moreau, P., additional

Published
2023
Full Text
View/download PDF

2. EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER 1–3 PRIOR LINES OF THERAPY: CARTITUDE-2 PHASE 2 STUDY

Author

Agha, ME, primary, Cohen, AD, additional, Madduri, D, additional, Cohen, YC, additional, Delforge, M, additional, Hillengass, J, additional, Goldschmidt, H, additional, Weisel, K, additional, Raab, M, additional, Scheid, C, additional, Schecter, JM, additional, Braganca, KC, additional, Varsos, H, additional, Wang, L, additional, Vogel, M, additional, Carrasco-Alfonso, MJ, additional, Akram, M, additional, Wu, X, additional, Nesheiwat, T, additional, and Einsele, H, additional

Published
2021
Full Text
View/download PDF

3. CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB VERSUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF THE PHASE 3 CANDOR STUDY BY NUMBER OF PRIOR LINES OFTHERAPY AND PRIOR THERAPIES

Author

Quach, H., primary, Nooka, A., additional, Samoylova, O., additional, Venner, C.P., additional, Facon, T., additional, Spencer, A., additional, Usmani, S.Z., additional, Weisel, K., additional, Mateos, M., additional, Kim, K., additional, Grosicki, S., additional, Suzuki, K., additional, Delimpasi, S., additional, Obreja, M., additional, and Zahlten-Kumeli, A., additional

Published
2020
Full Text
View/download PDF

4. POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS

Author

Dimopoulos, M., primary, Weisel, K., additional, Moreau, P., additional, Jr, L.D.A., additional, White, D., additional, Miguel, J.S., additional, Sonneveld, P., additional, Engelhardt, M., additional, Jenner, M., additional, Corso, A., additional, Dürig, J., additional, Pavic, M., additional, Salomo, M., additional, Casal, E., additional, Jiang, R., additional, Nguyen, T., additional, Peluso, T., additional, and Richardson, P., additional

Published
2020
Full Text
View/download PDF

6. BMT CTN myeloma intergroup workshop on minimal residual disease and immune profiling: summary and recommendations from the organizing committee

Author

Holstein, S.A. (Sarah A.), Avet-Loiseau, H. (Herve), Hahn, T. (Theresa), Ho, C.M. (Christine M.), Lohr, J.G. (Jens G.), Munshi, N.C. (Nikhil C.), Paiva, B. (Bruno), Pasquini, M.C. (Marcelo C.), Tario-Jr, J.D. (Joseph D.), Usmani, S.Z. (Saad Z.), Wallace, P.K. (Paul K.), Weisel, K. (Katja), and McCarthy, P.L. (Philip L.)

Subjects
Autologous stem cell transplant, Multiple myeloma, Minimal residual disease, Immune profiling
Abstract

The Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 1, 2016 at the American Society of Hematology meeting to discuss the emerging data and technologies for minimal residual disease assessment and immune profiling in myeloma. Particular emphasis was placed on developing strategies to incorporate these techniques into clinical trial design. This document reviews the literature, summarizes the topics discussed in the workshop, and provides recommendations for integration of these techniques into future clinical trial design.

Published
2018

7. Management of infusion-related reactions (IRRs) in patients (pts) receiving daratumumab plus standard of care for the treatment of multiple myeloma (MM) in the phase 3 studies CASTOR and POLLUX

Author

Moreau, P., primary, Rabin, N., additional, Plesner, T., additional, Weisel, K., additional, Sonneveld, P., additional, Mateos, M-V., additional, Schecter, J.M., additional, Amin, H., additional, Trivedi, S., additional, and Dimopoulos, M.A., additional

Published
2017
Full Text
View/download PDF

8. Phase 3 randomised study of daratumumab, bortezomib and dexamethasone (DVd) vs bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR

Author

Weisel, K., primary, Palumbo, A., additional, Chanan-Khan, A., additional, Nooka, A.K., additional, Spicka, I., additional, Masszi, T., additional, Beksac, M., additional, Hungria, V., additional, Munder, M., additional, Mateos, M.-V., additional, Mark, T.M., additional, Spencer, A., additional, Qi, M., additional, Schecter, J., additional, Amin, H., additional, Qin, X., additional, Deraedt, W., additional, Ahmadi, T., additional, and Sonneveld, P., additional

Published
2016
Full Text
View/download PDF

11. Updated Overall Survival (OS) Analysis of the FIRST Study: Lenalidomide Plus Low-Dose Dexamethasone (Rd) Continuous vs Melphalan, Prednisone, and Thalidomide (MPT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM)

Author

Facon, T., primary, Dimopoulos, M.A., additional, Hulin, C., additional, Benboubker, L., additional, Belch, A., additional, Ludwig, H., additional, Pinto, A., additional, Attal, M., additional, Cavo, M., additional, Moreau, P., additional, Schots, R., additional, Meuleman, N., additional, Weisel, K., additional, Tiab, M., additional, Lee, J.-J., additional, Butler, A., additional, Marek, J., additional, Chen, G., additional, Ervin-Haynes, A., additional, and Fermand, J.P., additional

Published
2015
Full Text
View/download PDF

12. Adverse Event (AE) Management With Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in the STRATUS(TM) Trial: A Phase 3b Study Evaluating Safety and Efficacy in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM)

Author

Cavo, M., primary, Dimopoulos, M.A., additional, Moreau, P., additional, Palumbo, A., additional, Corradini, P., additional, Weisel, K., additional, Ocio, E., additional, Doyen, C., additional, Anttila, P., additional, Raymakers, R., additional, San Miguel, J., additional, Knop, S., additional, Yu, X., additional, Milller, N., additional, Herring, J., additional, Slaughter, A., additional, Biyukov, T., additional, Peluso, T., additional, Sternas, L., additional, Zaki, M., additional, and Delforge, M., additional

Published
2015
Full Text
View/download PDF

13. A phase I/IIa study of the human CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma

Author

Raab, M.S., primary, Chatterjee, M., additional, Goldschmidt, H., additional, Agis, H., additional, Blau, I.W., additional, Einsele, H., additional, Engelhardt, M., additional, Ferstl, B., additional, Gramatzki, M., additional, Röllig, C., additional, Weisel, K., additional, Klöpfer, P., additional, Weinelt, D., additional, Härtle, S., additional, and Peschel, C., additional

Published
2015
Full Text
View/download PDF

14. STRATUS(TM) (MM 010): A Single Arm, Phase 3b Study Evaluating Safety and Efficacy of Pomalidomide (POM) + Low Dose Dexamethasone (LoDEX) in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM)

Author

Dimopoulos, M.A., primary, Palumbo, A., additional, Corradini, P., additional, Cavo, M., additional, Delforge, M., additional, Weisel, K., additional, Ocio, E., additional, Di Raimondo, F., additional, Rollig, C., additional, Oriol, A., additional, Simcock, M., additional, Miller, N., additional, Slaughter, A., additional, Biyukov, T., additional, Peluso, T., additional, Sternas, L., additional, Zaki, M., additional, and Moreau, P., additional

Published
2015
Full Text
View/download PDF

15. Health Resource Utilization with Continuous Lenalidomide Treatment (TX) in Elderly Patients (PTS) with newly diagnosed multiple myeloma (NDMM)

Author

Weisel, K., primary, Vogl, D., additional, Corso, A., additional, Delforge, M., additional, Song, K., additional, Dimopoulos, M.A., additional, Cavenagh, J., additional, Hulin, C., additional, Rodon, P., additional, Arnulf, B., additional, Foa, R., additional, Oriol, A., additional, Guo, S., additional, Catalano, J., additional, Gibson, C.J., additional, Van Oostendorp, J., additional, Ervin-Haynes, A., additional, and Facon, T., additional

Published
2015
Full Text
View/download PDF

18. The Treatment (Tx) of Patients (Pts) With Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: A Systematic Literature Review and Network Meta-Analysis

Author

Weisel, K., primary, Doyen, C., additional, Dimopoulos, M.A., additional, Yee, A., additional, Kropff, M., additional, Lahuerta, J.J., additional, Martin, A., additional, Travers, K., additional, Abildgaard, N., additional, Lu, J., additional, Van Droogenbroeck, J., additional, Geraldes, C., additional, Petrini, M., additional, Voillat, L., additional, Vilque, J.P., additional, Voog, E., additional, and Facon, T., additional

Published
2015
Full Text
View/download PDF

19. Outcomes of Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM) and Renal Impairment (RI) Treated With Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in the Phase 3b STRATUS(TM) Trial (MM-010)

Author

Weisel, K., primary, Dimopoulos, M.A., additional, Palumbo, A., additional, Corradini, P., additional, Cavo, M., additional, Delforge, M., additional, Ocio, E.M., additional, Vacca, A., additional, Hansson, M., additional, Blanchard, M., additional, Cook, G., additional, Miller, N., additional, Peluso, T., additional, Sternas, L., additional, Zaki, M., additional, and Moreau, P., additional

Published
2015
Full Text
View/download PDF

20. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Author

Michele Cavo, Laurent Garderet, Meletios A. Dimopoulos, Hartmut Goldschmidt, Valentina Ivanova, Philippe Moreau, Pieter Sonneveld, Xiaoyan Yu, Antonio Palumbo, Lars Sternas, Lionel Karlin, Steve Schey, Anne Banos, Andrew R. Belch, Kijoung Song, Joaquin Martinez-Lopez, Albert Oriol, Christopher T. Chen, Michel Delforge, Jesús F. San Miguel, Katja Weisel, Christian Jacques, Mohamed H. Zaki, Martha Q. Lacy, Adrian Alegre, San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M, Hematology, Cell biology, and Celgene

Subjects
Male, medicine.medical_specialty, Population, pomalidomide, Gastroenterology, Dexamethasone, Ixazomib, chemistry.chemical_compound, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Medicine, Elotuzumab, education, Multiple myeloma, Aged, Neoplasm Staging, Lenalidomide, Salvage Therapy, education.field_of_study, business.industry, Bortezomib, Prognosis, medicine.disease, Pomalidomide, Thalidomide, Surgery, Survival Rate, Oncology, chemistry, Drug Resistance, Neoplasm, Female, Neoplasm Recurrence, Local, Multiple Myeloma, business, Follow-Up Studies, medicine.drug
Abstract

[Background]: Few effective treatments exist for patients with refractory or relapsed and refractory multiple myeloma not responding to treatment with bortezomib and lenalidomide. Pomalidomide alone has shown limited efficacy in patients with relapsed multiple myeloma, but synergistic effects have been noted when combined with dexamethasone. We compared the efficacy and safety of pomalidomide plus low-dose dexamethasone with high-dose dexamethasone alone in these patients. [Methods]: This multicentre, open-label, randomised phase 3 trial was undertaken in Australia, Canada, Europe, Russia, and the USA. Patients were eligible if they had been diagnosed with refractory or relapsed and refractory multiple myeloma, and had failed at least two previous treatments of bortezomib and lenalidomide. They were assigned in a 2:1 ratio with a validated interactive voice and internet response system to either 28 day cycles of pomalidomide (4 mg/day on days 1-21, orally) plus low-dose dexamethasone (40 mg/day on days 1, 8, 15, and 22, orally) or high-dose dexamethasone (40 mg/day on days 1-4, 9-12, and 17-20, orally) until disease progression or unacceptable toxicity. Stratification factors were age (≤75 years vs >75 years), disease population (refractory vs relapsed and refractory vs bortezomib intolerant), and number of previous treatments (two vs more than two). The primary endpoint was progression-free survival (PFS). Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT01311687, and with EudraCT, number 2010-019820-30. [Findings]: The accrual for the study has been completed and the analyses are presented. 302 patients were randomly assigned to receive pomalidomide plus low-dose dexamethasone and 153 high-dose dexamethasone. After a median follow-up of 10·0 months (IQR 7·2-13·2), median PFS with pomalidomide plus low-dose dexamethasone was 4·0 months (95% CI 3·6-4·7) versus 1·9 months (1·9-2·2) with high-dose dexamethasone (hazard ratio 0·48 [95% CI 0·39-0·60]; p, Funding: Celgene Corporation.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results